Elena Castro
@Ecastromarcos
Followers
2K
Following
3K
Media
108
Statuses
1K
GU medical oncologist. Old enough to know better, young enough to keep learning
Spain
Joined June 2017
Our last paper in @Annals_Oncology: BRCA and HRR muts have similar prevalence in low and high volume mHSPC, but greater impact in low volume😯. Doublets with ARPi or docetaxel result in comparable poor outcomes for BRCA pts https://t.co/NJ5i6VEhEg
4
37
112
#ESMO25: Discover the latest #CancerResearch insights brought to you by #ESMOAmbassadors and join the conversation in #oncology. 🔗 https://t.co/YZZN0sQyBS
3
9
30
Precision medicine enters hormone sensitive prostate cancer therapeutics ! The first of many to follow
💫🌟Niraparib + Abiraterone + Prednisone in HRR-deficient mCSPC.🌟💫 https://t.co/35fsV1AVsS
@AttardLab @neerajaiims @SandhuShahneen @EfstathiouEleni @drgotto @heatherhcheng @Dolmos77 @drenriquegrande @DRathkopf
@uclcancer @huntsmancancer @seattlecca @fredhutch @uwmedicine
0
7
23
‼️LAST CALL 📍La Semana de la Ciencia de ASEICA 2025 comenzará con... ⚫RETREAT #ASEICAMed Keynote🗣️Ignacio Melero @ClinicaNavarra @CIMA_unav 📅7OCT 🏟️Bilbao ▶️Ciencia y Networking ‼️ Posibilidad de Registro único o a todo el #ASEICACongress
https://t.co/b8WKSMtjGV
0
5
8
👉Our new @ESMO_Open paper just OUT! Check the risk of VTE of PARPi in our meta-analysis! @myESMO @OncoAlert @DrYukselUrun @DrChoueiri @Erman_Akkus @APCCC_Lugano @DrRanaMcKay #cancer #Oncology #MedX @neerajaiims @maxinesun @Silke_Gillessen @Ecastromarcos
Our new meta-analysis has just been published! 🎉 PARP inhibitors may be linked to increased VTE risk overall ↗️ (2.4% vs 1.6%; OR 1.37; 95% CI 1.00–1.88). Signals vary by cancer type 🧬 Highlights: • Prostate cancer: higher VTE risk (OR 1.98; P=0.03) 📌 • Pancreatic cancer:
5
11
38
Submit an abstract by November 6 for the AACR Conference on Innovations in Prostate Cancer Research and Treatment (Jan 20-22; Boston), chaired by Peter S. Nelson, Elena Castro, Patrick G. Pilié, and Eliezer M. Van Allen. https://t.co/RPy49tc2qs
#AACRprostate26 @Ecastromarcos
2
5
5
0
7
12
#ESMO25 will be a fantastic meeting for GU oncology! Join us to discuss 5 impactful phase 3 trials #ProstateCancer @myESMO
1
14
37
👉 For ESMO Members! ESMO Handbook of Cancer Genetics and Genomics Edited by leading experts, delivering genomic literacy for clinical decision making: inherited genetic syndromes, key somatic and germline mutations, and more! 🔗 Download now: https://t.co/mbtzCXu63F
1
12
32
🎂 El Centro de Oncología Experimental del #Hospital12deOctubre cumple dos años. 🔬 Más de 100 investigadores y 156 estudios activos centrados en los tumores de mayor impacto. 👉 Referente nacional e internacional en cáncer. + info: https://t.co/LZBzo0BIwj
#somosdel12
1
25
56
Full professor complaining to an assistant professor on how hard it is to get funding nowadays
4
20
240
Submit an abstract by November 6 for the AACR Conference on Innovations in Prostate Cancer Research and Treatment (Jan 20-22; Boston), chaired by Peter S. Nelson, Elena Castro, Patrick G. Pilié, and Eliezer M. Van Allen. https://t.co/rs7MDaYNtC
#AACRprostate26 @Ecastromarcos
0
3
4
"We added the requested experiments and thank the reviewers for their helpful suggestions"
9
42
474
Abstract submission and scholar-in-training award applications are open until 6th November @AACR
1
0
8
A very sweet ending to a great #IUCS25 meeting!
The #IUCS25 came to an end!I want to congratulate @gbanna74 for the amazing organization, more importantly for his friendship!Great talks @neerajaiims @AlbigesL @PGrivasMDPhD @Ecastromarcos @alison_tree @drenriquegrande @montypal @RebuzziSara @DrYukselUrun and many others 🙌
0
1
7
CHAARTED Ten-year survival rates: Time to re-think de-escalation! Achieving a PSA nadir below 0.2 ng/mL within 6 months is a strong predictor of overall survival, supporting its role in response-adapted de-escalation strategies. @Annals_Oncology @myESMO @eaonc @ERPlimackMD
3
81
220
👏 Congratulations to @DrFelixGuerrero from @H12Octubre for this valuable collaboration between Urology & Oncology. A clear example of unity driving progress @cdanicas
🚨Interim results of SR-4 study published in @TheLancetOncol 📉pCR rate 42% 🔗Download it here: https://t.co/vrOk5UdIeF 🤩Glad to co-author this paper with @AndreaNecchi @BerUrologia @tompowles1 @BenjaminPradere among others!
2
6
24
APCCC is already a classic, but have you checked the program for the International Prostate Cancer Symposium #IPCS26? The 2 days before APCCC, available both in person and on-line. https://t.co/HKLMjHOiJE
warm invite to the Advanced Prostate Cancer Consensus Conference #APCCC26 in Lugano🇨🇭 👉REGISTER HERE: https://t.co/zPDe03TBd7 In an era of rapid innovation and expanding treatment options for advanced #ProstateCancer , APCCC provides a vital forum for clinicians and
0
8
26
Terbium-161 vs lutetium-177: Comparing next-gen radioligands for #ProstateCancer. @DrMHofman @PeterMacCC joins Oliver Sartor, MD @EJHospital to discuss the #VIOLET study evaluating Terbium-161 PSMA therapy in #mCRPC. #WatchNow > https://t.co/xG6uE2HGW6
0
7
17
I'm pleased to launch a new series, "Science Matters." We’ll explore why science matters, and which scientific 'matters' are key to translating cancer breakthroughs into better care for patients everywhere. I hope you enjoy the first installment!
connection.asco.org
2025-2026 ASCO president Dr. Eric Small introduces “Science Matters,” a series of interviews and videos which will discuss how scientific discovery drives real-world change.
4
35
91
Germline variants with therapeutic implications in prostate cancer. It has been a pleasure to work with @BitarafMasoudMD and @NimaSharifiMD in this review focused on the role of HSD3B1 and BRCA2👇 https://t.co/pHcvvgguAK
3
13
43